• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

杆状病毒表达的靶向S蛋白的自组装新型冠状病毒纳米颗粒疫苗可诱导小鼠产生保护性免疫。

Baculovirus-expressed self-assembling SARS-CoV-2 nanoparticle vaccines targeting the S protein induce protective immunity in mice.

作者信息

Liu Xingjian, Song Haozhi, Jiang Jianmin, Gao Xintao, Yi Yongzhu, Shang Yuting, Li Jialei, Li Dan, Zeng Zhen, Li Yinü, Zhang Zhifang

机构信息

Biotechnology Research Institute, Chinese Academy of Agricultural Sciences, Beijing, China.

Key Laboratory of Vaccine, Prevention and control of Infectious disease of Zhejiang Province, Zhejiang Provincial Center For Disease Control And Prevention, Hangzhou, Zhejiang Province, China.

出版信息

Process Biochem. 2023 Jun;129:200-208. doi: 10.1016/j.procbio.2023.03.026. Epub 2023 Mar 24.

DOI:10.1016/j.procbio.2023.03.026
PMID:37007452
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10038678/
Abstract

Spike (S) protein, a homotrimeric glycoprotein, is the most important antigen target for SARS-CoV-2 vaccines. A complete simulation of the advanced structure of this homotrimer during subunit vaccine development is the most likely method to improve its immunoprotective effects. In this study, preparation strategies for the S protein receptor-binding domain, S1 region, and ectodomain trimer nanoparticles were designed using ferritin nanoparticle self-assembly technology. The Bombyx mori baculovirus expression system was used to prepare three nanoparticle vaccines with high expression levels recorded in silkworms. The results in mice showed that the nanoparticle vaccine prepared using this strategy could induce immune responses when administered via both the subcutaneous administration and oral routes. Given the stability of these ferritin-based nanoparticle vaccines, an easy-to-use and low-cost oral immunization strategy can be employed in vaccine blind areas attributed to shortages of ultralow-temperature equipment and medical resources in underdeveloped areas. Oral vaccines are also promising candidates for limiting the spread of SARS-CoV-2 in domestic and farmed animals, especially in stray and wild animals.

摘要

刺突(S)蛋白是一种同源三聚体糖蛋白,是新冠病毒疫苗最重要的抗原靶点。在亚单位疫苗研发过程中,对这种同源三聚体的高级结构进行完整模拟是提高其免疫保护效果的最可行方法。在本研究中,利用铁蛋白纳米颗粒自组装技术设计了S蛋白受体结合域、S1区域和胞外域三聚体纳米颗粒的制备策略。采用家蚕杆状病毒表达系统制备了三种在蚕中表达水平较高的纳米颗粒疫苗。小鼠实验结果表明,采用该策略制备的纳米颗粒疫苗经皮下和口服途径给药均可诱导免疫反应。鉴于这些基于铁蛋白的纳米颗粒疫苗的稳定性,在欠发达地区因超低温设备和医疗资源短缺而导致的疫苗接种盲区,可采用一种易于使用且低成本的口服免疫策略。口服疫苗也是限制新冠病毒在家养动物和农场动物中传播的有前景的候选疫苗,尤其是在流浪动物和野生动物中。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8796/10038678/cdbec3f94627/ga1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8796/10038678/cdbec3f94627/ga1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8796/10038678/cdbec3f94627/ga1_lrg.jpg

相似文献

1
Baculovirus-expressed self-assembling SARS-CoV-2 nanoparticle vaccines targeting the S protein induce protective immunity in mice.杆状病毒表达的靶向S蛋白的自组装新型冠状病毒纳米颗粒疫苗可诱导小鼠产生保护性免疫。
Process Biochem. 2023 Jun;129:200-208. doi: 10.1016/j.procbio.2023.03.026. Epub 2023 Mar 24.
2
Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants.两亲性纳米颗粒疫苗展示糖基化 Spike S1 结构域,诱导针对 SARS-CoV-2 变体的中和抗体反应。
mBio. 2021 Oct 26;12(5):e0181321. doi: 10.1128/mBio.01813-21. Epub 2021 Oct 12.
3
Induction of Broadly Cross-Reactive Antibody Responses to SARS-CoV-2 Variants by S1 Nanoparticle Vaccines.S1 纳米颗粒疫苗诱导针对 SARS-CoV-2 变体的广泛交叉反应性抗体应答。
J Virol. 2022 Jul 13;96(13):e0038322. doi: 10.1128/jvi.00383-22. Epub 2022 Jun 14.
4
An Engineered Receptor-Binding Domain Improves the Immunogenicity of Multivalent SARS-CoV-2 Vaccines.一种工程化受体结合域可提高多价SARS-CoV-2疫苗的免疫原性。
mBio. 2021 May 11;12(3):e00930-21. doi: 10.1128/mBio.00930-21.
5
Optimization of SARS-CoV-2 Spike Protein Expression in the Silkworm and Induction of Efficient Protective Immunity by Inoculation With Alum Adjuvants.利用家蚕表达 SARS-CoV-2 刺突蛋白的优化及其与佐剂 Alum 共接种诱导高效保护免疫
Front Immunol. 2022 Jan 12;12:803647. doi: 10.3389/fimmu.2021.803647. eCollection 2021.
6
Oral subunit SARS-CoV-2 vaccine induces systemic neutralizing IgG, IgA and cellular immune responses and can boost neutralizing antibody responses primed by an injected vaccine.口服亚单位 SARS-CoV-2 疫苗可诱导全身中和 IgG、IgA 和细胞免疫应答,并能增强已接种疫苗产生的中和抗体应答。
Vaccine. 2022 Feb 16;40(8):1098-1107. doi: 10.1016/j.vaccine.2022.01.025. Epub 2022 Jan 19.
7
Insight into vaccine development for Alpha-coronaviruses based on structural and immunological analyses of spike proteins.基于刺突蛋白的结构和免疫学分析对甲型冠状病毒疫苗研发的见解。
J Virol. 2021 Mar 10;95(7). doi: 10.1128/JVI.02284-20. Epub 2021 Jan 7.
8
Peritoneal Administration of a Subunit Vaccine Encapsulated in a Nanodelivery System Not Only Augments Systemic Responses against SARS-CoV-2 but Also Stimulates Responses in the Respiratory Tract.纳米递药系统包裹的亚单位疫苗经腹腔给药不仅增强了针对 SARS-CoV-2 的全身反应,还刺激了呼吸道的反应。
Viruses. 2021 Nov 2;13(11):2202. doi: 10.3390/v13112202.
9
S Trimer Derived from SARS-CoV-2 B.1.351 and B.1.618 Induced Effective Immune Response against Multiple SARS-CoV-2 Variants.源自新冠病毒B.1.351和B.1.618的S三聚体诱导了针对多种新冠病毒变体的有效免疫反应。
Vaccines (Basel). 2023 Jan 16;11(1):193. doi: 10.3390/vaccines11010193.
10
Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design.重组杆状病毒表达的严重急性呼吸综合征冠状病毒刺突蛋白的抗原性和免疫原性特征:对疫苗设计的启示
J Virol. 2006 Jun;80(12):5757-67. doi: 10.1128/JVI.00083-06.

引用本文的文献

1
Baculovirus-mediated production and purification of ferritin nanoparticles for rift valley fever vaccine development.杆状病毒介导的用于裂谷热疫苗开发的铁蛋白纳米颗粒的生产与纯化
J Biol Eng. 2025 Aug 14;19(1):75. doi: 10.1186/s13036-025-00550-8.
2
Construction and immunogenicity analysis of a recombinant baculovirus targeting the N protein of SARS-CoV-2.一种靶向严重急性呼吸综合征冠状病毒2(SARS-CoV-2)N蛋白的重组杆状病毒的构建及免疫原性分析
Biotechnol Lett. 2025 Apr 16;47(3):42. doi: 10.1007/s10529-025-03576-6.
3
A Ferritin-Based Eg95 Nanoparticle Vaccine Adjuvanted with pCpG Eliciting Robust Immune Responses Against Cystic Echinococcosis in Mice Model.

本文引用的文献

1
Protection against SARS-CoV-2 Omicron BA.1 variant challenge in macaques by prime-boost vaccination with Ad26.COV2.S and SpFN.用Ad26.COV2.S和SpFN进行初免-加强免疫接种可保护猕猴免受SARS-CoV-2奥密克戎BA.1变体攻击。
Sci Adv. 2022 Nov 25;8(47):eade4433. doi: 10.1126/sciadv.ade4433. Epub 2022 Nov 23.
2
Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine.纳米颗粒疫苗诱导的 SARS-CoV-2 中和与保护的广谱性。
Nat Commun. 2022 Oct 23;13(1):6309. doi: 10.1038/s41467-022-33985-4.
3
Development of a ferritin-based nanoparticle vaccine against the SARS-CoV-2 Omicron variant.
一种基于铁蛋白的Eg95纳米颗粒疫苗,佐以pCpG,在小鼠模型中引发针对囊型包虫病的强烈免疫反应。
Int J Nanomedicine. 2025 Jan 8;20:309-325. doi: 10.2147/IJN.S499938. eCollection 2025.
4
Exigency of Plant-Based Vaccine against COVID-19 Emergence as Pandemic Preparedness.基于植物的新冠疫苗作为大流行防范措施出现的紧迫性。
Vaccines (Basel). 2023 Aug 9;11(8):1347. doi: 10.3390/vaccines11081347.
5
Application of Baculovirus Expression Vector system (BEV) for COVID-19 diagnostics and therapeutics: a review.杆状病毒表达载体系统(BEV)在新冠病毒诊断与治疗中的应用:综述
J Genet Eng Biotechnol. 2022 Jul 6;20(1):98. doi: 10.1186/s43141-022-00368-7.
6
Nanoparticles for Coronavirus Control.用于控制冠状病毒的纳米颗粒。
Nanomaterials (Basel). 2022 May 9;12(9):1602. doi: 10.3390/nano12091602.
7
The self-assembled nanoparticle-based trimeric RBD mRNA vaccine elicits robust and durable protective immunity against SARS-CoV-2 in mice.基于自组装纳米颗粒的三聚体 RBD mRNA 疫苗在小鼠中引发针对 SARS-CoV-2 的强大和持久的保护性免疫。
Signal Transduct Target Ther. 2021 Sep 9;6(1):340. doi: 10.1038/s41392-021-00750-w.
一种针对新冠病毒奥密克戎变异株的基于铁蛋白的纳米颗粒疫苗的研发。
Signal Transduct Target Ther. 2022 Jun 1;7(1):173. doi: 10.1038/s41392-022-01041-8.
4
Oral and intranasal vaccines against SARS-CoV-2: Current progress, prospects, advantages, and challenges.针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的口服和鼻内疫苗:当前进展、前景、优势及挑战
Immun Inflamm Dis. 2022 Apr;10(4):e604. doi: 10.1002/iid3.604.
5
A Thermostable Oral SARS-CoV-2 Vaccine Induces Mucosal and Protective Immunity.一种耐热的口服 SARS-CoV-2 疫苗可诱导黏膜和保护性免疫。
Front Immunol. 2022 Feb 25;13:837443. doi: 10.3389/fimmu.2022.837443. eCollection 2022.
6
SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity.严重急性呼吸综合征冠状病毒2型铁蛋白纳米颗粒疫苗引发广泛的严重急性呼吸综合征冠状病毒免疫原性。
Cell Rep. 2021 Dec 21;37(12):110143. doi: 10.1016/j.celrep.2021.110143. Epub 2021 Dec 8.
7
A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates.一种 SARS-CoV-2 铁蛋白纳米颗粒疫苗在非人灵长类动物中引发保护性免疫应答。
Sci Transl Med. 2022 Feb 16;14(632):eabi5735. doi: 10.1126/scitranslmed.abi5735.
8
The oral vaccine based on self-replicating RNA lipid nanoparticles can simultaneously neutralize both SARS-CoV-2 variants alpha and delta.基于自我复制 RNA 脂质纳米颗粒的口服疫苗可同时中和 SARS-CoV-2 的阿尔法和德尔塔变体。
Int Immunopharmacol. 2021 Dec;101(Pt B):108231. doi: 10.1016/j.intimp.2021.108231. Epub 2021 Oct 7.
9
Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants.两亲性纳米颗粒疫苗展示糖基化 Spike S1 结构域,诱导针对 SARS-CoV-2 变体的中和抗体反应。
mBio. 2021 Oct 26;12(5):e0181321. doi: 10.1128/mBio.01813-21. Epub 2021 Oct 12.
10
Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study.健康成年人中新型冠状病毒重组蛋白疫苗制剂的安全性和免疫原性:一项随机、安慰剂对照、1-2 期、剂量范围研究的中期结果。
Lancet Infect Dis. 2021 Sep;21(9):1257-1270. doi: 10.1016/S1473-3099(21)00147-X. Epub 2021 Apr 19.